Dianthus Therapeutics Correlations
| DNTH Stock | 20.27 0.50 2.41% |
The current 90-days correlation between Dianthus Therapeutics and Zura Bio Limited is 0.34 (i.e., Weak diversification). The correlation of Dianthus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Dianthus Therapeutics Correlation With Market
Weak diversification
The correlation between Dianthus Therapeutics and DJI is 0.3 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Dianthus Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Dianthus |
Moving together with Dianthus Stock
Moving against Dianthus Stock
| 0.34 | RNXT | RenovoRx | PairCorr |
| 0.68 | DIS | Walt Disney Aggressive Push | PairCorr |
| 0.55 | RDNT | RadNet Inc | PairCorr |
| 0.44 | WMT | Walmart Aggressive Push | PairCorr |
| 0.43 | T | ATT Inc Aggressive Push | PairCorr |
| 0.42 | BAC | Bank of America Aggressive Push | PairCorr |
| 0.39 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.34 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.32 | JPM | JPMorgan Chase Fiscal Year End 10th of January 2025 | PairCorr |
Related Correlations Analysis
| 0.68 | -0.08 | 0.34 | -0.19 | -0.05 | ZVSA | ||
| 0.68 | 0.03 | 0.55 | -0.22 | -0.02 | SONN | ||
| -0.08 | 0.03 | 0.25 | 0.54 | 0.29 | ZURA | ||
| 0.34 | 0.55 | 0.25 | 0.14 | -0.14 | PHIO | ||
| -0.19 | -0.22 | 0.54 | 0.14 | -0.03 | RNAZ | ||
| -0.05 | -0.02 | 0.29 | -0.14 | -0.03 | QNRX | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Dianthus Stock performing well and Dianthus Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Dianthus Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ZVSA | 4.67 | (0.99) | 0.00 | 0.60 | 0.00 | 9.17 | 78.93 | |||
| SONN | 4.76 | (0.77) | 0.00 | 2.19 | 0.00 | 12.31 | 37.58 | |||
| ZURA | 3.78 | (0.36) | 0.00 | (0.09) | 0.00 | 7.95 | 30.69 | |||
| PHIO | 4.53 | (0.30) | 0.00 | (0.18) | 0.00 | 11.78 | 36.22 | |||
| RNAZ | 7.63 | 1.05 | 0.10 | (0.44) | 6.52 | 22.00 | 68.80 | |||
| QNRX | 6.21 | 0.47 | 0.07 | 0.37 | 6.73 | 17.65 | 74.46 |
Dianthus Therapeutics Corporate Management
| Jennifer Ruff | VP Affairs | Profile | |
| Edward Carr | Chief Officer | Profile | |
| Kristina Maximenko | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile | |
| Adam Esq | General Counsel | Profile | |
| Judson Taylor | Head Operations | Profile |